- Home
- EVTV vs DRMA Comparison
EVTV vs DRMA Comparison
Compare EVTV & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVTV | DRMA |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 2.3M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EVTV | DRMA |
|---|---|---|
| Price | $0.39 | $2.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 2.2M | ★ 2.4M |
| Earning Date | 11-20-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,696,856.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 113.69 | N/A |
| 52 Week Low | $0.33 | $1.58 |
| 52 Week High | $14.00 | $23.70 |
Technical Indicators
Market Signals| Indicator | EVTV | DRMA |
|---|---|---|
| Relative Strength Index (RSI) | 24.87 | 42.84 |
| Support Level | $0.33 | $2.03 |
| Resistance Level | $0.52 | $2.58 |
| Average True Range (ATR) | 0.13 | 0.32 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 6.45 | 49.41 |
Price Performance
Historical ComparisonAbout EVTV Envirotech Vehicles Inc.
Envirotech Vehicles Inc is a provider of purpose-built zero-emission electric vehicles focused on reducing the total cost of vehicle ownership and helping fleet operators unlock the benefits of green technology. It recognizes revenue from the sales of zero-emission electric vehicles and vehicle maintenance and inspection services. The Company serves commercial and last-mile fleets, school districts, public and private transportation service companies and colleges and universities to meet the increasing demand for light to heavy-duty electric vehicles.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.